DED Magnified: A Real-World Case Library – Case 3

Overview

Activity Description and Purpose

Most patients with cataracts also have dry eye disease (DED), and optimization of the ocular surface prior to cataract surgery is crucial for successful surgical outcomes. More recent additions to an already large treatment armamentarium available for DED can make it challenging to select the treatment(s) that will successfully manage a patient’s DED quickly so that surgery can proceed. In this third case of the DED Magnified: A Real-World Case Library series, Sheri Rowan, MD, walks through her effective and successful treatment of a patient with DED and severe bilateral cataracts.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

• Review causative factors of dry eye disease
• Design evidence-based treatment plans for persons with dry eye disease

Registration Instructions

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.

Faculty Credentials

Faculty

Sheri Rowen, MD NVISION Eye Center Newport Beach, California

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Sheri Rowen, MD, is a consultant for AbbVie Inc, Atia Vision, Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, OcuTerra Therapeutics, Orasis Pharmaceuticals, and RxSIGHT; is on the speakers bureau for AceVision, Atia Vision, Inc, Bausch & Lomb Incorporated, Orasis Pharmaceuticals, RxSIGHT, and ScienceBased Health; is an advisory board member of Centricity Vision, Inc, Thea Pharmaceuticals Limited, and Visus Therapeutics; and has stock options that have not been exercised in Orasis Pharmaceuticals.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation